Janus Henderson Group’s KalVista Pharmaceuticals KALV Stock Holding History

Janus Henderson Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$220K	Hold	10,900	–	–	﹤0.01%	2309
2025 Q4	$176K	Hold	10,900	–	–	﹤0.01%	2362
2025 Q3	$133K	Buy	+10,900	New	+$151K	﹤0.01%	2378
2021 Q4	–	Sell	-1,141,683	Closed	-$19.9M	–	2569
2021 Q3	$19.9M	Sell	1,141,683 -27,917	-2%	-$566K	0.01%	798
2021 Q2	$28M	Buy	1,169,600 +35,828	+3%	+$937K	0.01%	712
2021 Q1	$29.1M	Buy	1,133,772 +973,261	+606%	+$25.6M	0.01%	689
2020 Q4	$3.05M	Sell	160,511 -8,498	-5%	-$146K	﹤0.01%	1060
2020 Q3	$2.13M	Buy	169,009 +8,233	+5%	+$103K	﹤0.01%	1047
2020 Q2	$1.94M	Buy	160,776 +8,469	+6%	+$90.1K	﹤0.01%	1036
2020 Q1	$1.17M	Buy	152,307 +136,392	+857%	+$1.84M	﹤0.01%	1081
2019 Q4	$283K	Buy	+15,915	New	+$208K	﹤0.01%	1351

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Janus Henderson Group's KALV Position: Q1 2026 in Review

Janus Henderson Group held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 10,900 shares worth $220K. The position accounts for ﹤0.01% of the portfolio, ranked #2309.

Janus Henderson Group first reported a position in KALV in Q4 2019 and has held it in 11 quarters since. The position peaked at $29.1M in Q1 2021. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Janus Henderson Group held 10,900 shares of KalVista Pharmaceuticals worth $220K as of Q1 2026.
Janus Henderson Group left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
KalVista Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #2309 holding.
Janus Henderson Group first reported a position in KalVista Pharmaceuticals in Q4 2019 and has held it in 11 quarters since.
Janus Henderson Group's KalVista Pharmaceuticals position peaked at $29.1M in Q1 2021.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.